Skyhawk Therapeutics anuncia los resultados finales de 15 meses del ensayo clínico de fase 1/2 de SKY-0515

Phase 1SKY-0515Neutral

AI Analysis

Summary

Skyhawk Therapeutics announced final 15-month results from a Phase 1/2 clinical trial of SKY-0515 in patients with Huntington's disease. The dataset represents the final analysis of the Phase 1/2 study.

Clinical Trial Data

Phase

1/2

Outcome Details

15-month final analysis of Phase 1/2 study

Importance:5/10

Sentiment:

0.00

clinical trialHuntington's diseasePhase 1/2SKY-0515

Read the original article

Published by PR Newswire Pharma on September 16, 2026 10:27 AM

Read Original